DNTH NASDAQ
Dianthus Therapeutics, Inc.
1W: +1.0%
1M: -9.5%
3M: -23.6%
YTD: +100.4%
1Y: +141.6%
3Y: +539.7%
5Y: -22.1%
$79.52
+0.19 (+0.24%)
Weekly Expected Move ±5.4%
$69
$73
$77
$81
$85
Credit Risk of going bust: lower than 91% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Dianthus Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.3M against a stock market value of $4.45B.
Distance to default 14.65 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $644K (short-term plus half of long-term), stock volatility 59.4%; Altman Z'' 33.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Dianthus Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.3M against a stock market value of $4.45B.
Distance to default 14.65 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $644K (short-term plus half of long-term), stock volatility 59.4%; Altman Z'' 33.19. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-08-04
Earliest Filing
2025-10-16
Latest Filing
partner: 3
supplier: 1
Counterparties (Filed by DNTH)
4 relationshipsCompanies named in DNTH's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Nanjing Leads Biolabs Co. Ltd. | — | partner | License and Collaboration Agreement for exclusive rights to develop and commercialize DNTH212 outside of Greater China | 2025-10-16 | View |
| Novartis Institutes for Biomedical Research, Inc. | NVSEF | supplier | Counterparty to Sublease Termination and Release Agreement regarding office space lease termination. | 2023-04-06 | View |
| Computershare Trust Company, N.A. | — | partner | Appointed as Rights Agent for the Stockholder Rights Agreement | 2023-03-31 | View |
| Heidelberg Pharma Research GmbH | — | partner | Entered into an amendment to an exclusive research, development option and license agreement with Magenta Therapeutics, | 2022-08-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-06-12 | Other Events; Exhibits | View | |
| 2026-05-22 | Shareholder Vote | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-03-26 | Other Events; Exhibits | View | |
| 2026-03-12 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-03-09 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-16 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Other Event | Agreement | View |
| 2025-09-11 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-09-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-22 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-12-12 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR